Study designs of evaluations included in the review
Randomised controlled trials (RCTs), phase II studies and case series.
Specific interventions included in the review
Vinorelbine as first line therapy in advanced NSCLC: Vinorelbine plus cisplatin versus other regimens; Vinorelbine versus vinorelbine plus cisplatin; Vinorelbine versus other single agents. Phase II studies of single agent vinorelbine in advanced NSCLC. Vinorelbine as second-line therapy in NSCLC.
Participants included in the review
Patients with non-small-cell lung cancer.
Outcomes assessed in the review
Survival is the primary end point of interest. Response and toxicity are secondary end points.
How were decisions on the relevance of primary studies made?
The authors do not state how the papers were selected for the review, or how many of the authors performed the selection.